Neoplasia (PET)

Warning: Undefined array key "S1" in C:\Inetpub\vhosts\kidney.de\httpdocs\bdom\Neoplasia (PET).php on line 2
Neoplasia (PET)

LE WE PMID CA

Neoplasia (PET)

5989

Neubildung (PET)

MRT (DCE MRI)

MRT (Instrumentation)

Neoplasia (Imaging)

Neoplasia (MRS)

Neoplasia (MRT)

Neoplasia (PET)

Neoplasia (Unknown primary tumor)

Positron emission tomography (Method)

Radiation therapy

2002 1	The value of positron emission tomography (PET) imaging in disease staging and therapy assessment. [12401695] Ann Oncol 13 Suppl 4(-): 227-34 (2002)
1993 2	Clinical applications of positron-emission tomography in cancer. [8324656] CA Cancer J Clin 43(4): 235-54 (1993)
2007 3	Tumor-specific positron emission tomography imaging in patients: [18F] fluorodeoxyglucose and beyond. [17575208] Clin Cancer Res 13(12): 3460-9 (2007)
2006 4	Present role and future prospects of positron emission tomography in clinical oncology. [17052261] Cancer Sci 97(12): 1291-7 (2006)
2006 5	18FDG PET in oncology: the best and the worst (Review). [16596242] Int J Oncol 28(5): 1249-61 (2006)
2007 6	Brain abnormalities detected on whole-body 18F-FDG PET in cancer patients: spectrum of findings. [17312080] AJR Am J Roentgenol 188(3): 866-73 (2007)
2001 7	From tumor biology to clinical Pet: a review of positron emission tomography (PET) in oncology. [11831394] Ann Nucl Med 15(6): 471-86 (2001)
2002 8	Clinical applications of (18)F-FDG in oncology. [11948260] J Nucl Med Technol 30(1): 3-9; quiz 10-1 (2002)
2009 9	18F-FDG uptake in lung, breast, and colon cancers: molecular biology correlates and disease characterization. [19837767] J Nucl Med 50(11): 1820-7 (2009)
2009 10	From RECIST to PERCIST: Evolving Considerations for PET response criteria in solid tumors. [19403881] J Nucl Med 50 Suppl 1(-): 122S-50S (2009)
2009 11	18F-FDG PET and PET/CT in the evaluation of cancer treatment response. [19139187] J Nucl Med 50(1): 88-99 (2009)
2008 12	PET imaging of cancer immunotherapy. [18511842] J Nucl Med 49(6): 865-8 (2008)
2008 13	Recommendations on the use of 18F-FDG PET in oncology. [18287273] J Nucl Med 49(3): 480-508 (2008)
2008 14	18F-FDG PET for posttherapy assessment of Hodgkin's disease and aggressive Non-Hodgkin's lymphoma: a systematic review. [18077527] J Nucl Med 49(1): 13-21 (2008)
2008 15	18F-FDG PET as a routine test for posttherapy assessment of Hodgkin's disease and aggressive non-Hodgkin's lymphoma: where is the evidence? [18077522] J Nucl Med 49(1): 9-12 (2008)
2007 16	Clinical applications of PET in brain tumors. [17704239] J Nucl Med 48(9): 1468-81 (2007)
2007 17	Partial-volume effect in PET tumor imaging. [17504879] J Nucl Med 48(6): 932-45 (2007)
2007 18	Improvements in cancer staging with PET/CT: literature-based evidence as of September 2006. [17204723] J Nucl Med 48 Suppl 1(-): 78S-88S (2007)
2007 19	PET-based treatment planning in radiotherapy: a new standard? [17204722] J Nucl Med 48 Suppl 1(-): 68S-77S (2007)
2007 20	Clinical role of 18F-FDG PET/CT in the management of squamous cell carcinoma of the head and neck and thyroid carcinoma. [17204721] J Nucl Med 48 Suppl 1(-): 58S-67S (2007)
2007 21	Can PET/CT replace separate diagnostic CT for cancer imaging? Optimizing CT protocols for imaging cancers of the chest and abdomen. [17204720] J Nucl Med 48 Suppl 1(-): 45S-57S (2007)
2007 22	Monitoring cancer treatment with PET/CT: does it make a difference? [17204719] J Nucl Med 48 Suppl 1(-): 36S-44S (2007)
2007 23	Early detection of cancer recurrence: 18F-FDG PET/CT can make a difference in diagnosis and patient care. [17204718] J Nucl Med 48 Suppl 1(-): 28S-35S (2007)
2007 24	Integrating PET and PET/CT into the risk-adapted therapy of lymphoma. [17204717] J Nucl Med 48 Suppl 1(-): 19S-27S (2007)
2007 25	Screening for cancer with PET and PET/CT: potential and limitations. [17204716] J Nucl Med 48 Suppl 1(-): 4S-18S (2007)
2006 26	Consensus recommendations for the use of 18F-FDG PET as an indicator of therapeutic response in patients in National Cancer Institute Trials. [16741317] J Nucl Med 47(6): 1059-66 (2006)
2006 27	18F-FDG PET as a candidate for "qualified biomarker": functional assessment of treatment response in oncology. [16741296] J Nucl Med 47(6): 901-3 (2006)
2006 28	Procedure guideline for tumor imaging with 18F-FDG PET/CT 1.0. [16644760] J Nucl Med 47(5): 885-95 (2006)
2006 29	PET evaluation of lung cancer. [16513615] J Nucl Med 47(3): 451-69 (2006)
2005 30	Oncologic imaging in gynecologic malignancies. [16269598] J Nucl Med 46(11): 1842-50 (2005)
2005 31	Use of PET for monitoring cancer therapy and for predicting outcome. [15937310] J Nucl Med 46(6): 983-95 (2005)
2005 32	18F-FDG PET for evaluation of bone marrow infiltration in staging of lymphoma: a meta-analysis. [15937306] J Nucl Med 46(6): 958-63 (2005)
2004 33	Why nearly all PET of abdominal and pelvic cancers will be performed as PET/CT. [14736839] J Nucl Med 45 Suppl 1(-): 82S-95S (2004)
2004 34	PET/CT in oncology: integration into clinical management of lymphoma, melanoma, and gastrointestinal malignancies. [14736838] J Nucl Med 45 Suppl 1(-): 72S-81S (2004)
2004 35	Why most PET of lung and head-and-neck cancer will be PET/CT. [14736837] J Nucl Med 45 Suppl 1(-): 66S-71S (2004)
2004 36	PET in the assessment of therapy response in patients with carcinoma of the head and neck and of the esophagus. [14734674] J Nucl Med 45(1): 56-68 (2004)
2003 37	Meta-analysis of the performance of 18F-FDG PET in primary tumor detection in unknown primary tumors. [12902422] J Nucl Med 44(8): 1301-14 (2003)
2003 38	18F-FDG PET evaluation of the response to therapy for lymphoma and for breast, lung, and colorectal carcinoma. [12571214] J Nucl Med 44(2): 224-39 (2003)
2000 39	The diagnostic utility of the lognormal behavior of PET standardized uptake values in tumors. [11037996] J Nucl Med 41(10): 1664-72 (2000)
2000 40	A meta-analysis of the literature for whole-body FDG PET detection of recurrent colorectal cancer. [10914907] J Nucl Med 41(7): 1177-89 (2000)
1999 41	Potential applications of PET imaging in developing novel cancer therapies. [10452317] J Nucl Med 40(6): 995-1002 (1999)
1999 42	Oncological applications of FDG PET imaging: brain tumors, colorectal cancer, lymphoma and melanoma. [10210218] J Nucl Med 40(4): 591-603 (1999)
1998 43	Procedure guideline for tumor imaging using fluorine-18-FDG. Society of Nuclear Medicine. [9669415] J Nucl Med 39(7): 1302-5 (1998)
2000 44	FDG PET of recurrent or metastatic 131I-negative papillary thyroid carcinoma. [10855626] J Nucl Med 41(6): 1010-5 (2000)
1999 45	Oncological applications of FDG PET imaging. [10520713] J Nucl Med 40(10): 1706-15 (1999)
1991 46	The applications of PET in clinical oncology. [2013803] J Nucl Med 32(4): 623-48; discussion 649-50 (1991)
2003 47	Clinical role of FDG PET in evaluation of cancer patients. [12640150] Radiographics 23(2): 315-40; quiz 533 (2003)
1999 48	Pitfalls in oncologic diagnosis with FDG PET imaging: physiologic and benign variants. [9925392] Radiographics 19(1): 61-77; quiz 150-1 (1999)
2004 49	Clinical applications of PET in oncology. [15044750] Radiology 231(2): 305-32 (2004)
2009 50	Measuring response with FDG-PET: methodological aspects. [19357228] Oncologist 14(4): 369-77 (2009)
2008 51	Use of H2(15)O-PET and DCE-MRI to measure tumor blood flow. [18586918] Oncologist 13(6): 631-44 (2008)
2010 52	Hypoxia PET/CT imaging: implications for radiation oncology. [20927017] Q J Nucl Med Mol Imaging 54(5): 500-9 (2010)
2004 53	PET/CT in diagnostic oncology. [15243404] Q J Nucl Med Mol Imaging 48(2): 66-75 (2004)
2007 54	Somatostatin receptor PET imaging with Gallium-68 labeled peptides. [17464267] Q J Nucl Med Mol Imaging 51(3): 244-50 (2007)
2007 55	PET in genitourinary tract cancers. [17464269] Q J Nucl Med Mol Imaging 51(3): 260-71 (2007)
2009 56	Assessing tumor hypoxia by positron emission tomography with Cu-ATSM. [19293767] Q J Nucl Med Mol Imaging 53(2): 193-200 (2009)
2008 57	Oncologic PET tracers beyond [(18)F]FDG and the novel quantitative approaches in PET imaging. [18235421] Q J Nucl Med Mol Imaging 52(1): 50-65 (2008)
2010 58	Tumor pH and its measurement. [20660380] J Nucl Med 51(8): 1167-70 (2010)
2010 59	Proton therapy dosimetry using positron emission tomography. [21160579] World J Radiol 2(4): 135-42 (2010)
2010 60	Methodological considerations in quantification of oncological FDG PET studies. [19936745] Eur J Nucl Med Mol Imaging 37(7): 1408-25 (2010)
2010 61	FDG PET/CT in carcinoma of unknown primary. [19882152] Eur J Nucl Med Mol Imaging 37(3): 635-44 (2010)
2011 62	FDG-PET for hepatobiliary and pancreatic cancer: Advances and current limitations. [21611100] World J Clin Oncol 2(5): 229-36 (2011)
2011 63	Molecular imaging in oncology: the acceptance of PET/CT and the emergence of MR/PET imaging. [21174096] Eur Radiol 21(3): 548-54 (2011)
2009 64	Combined FDG-PET/CT for the detection of unknown primary tumors: systematic review and meta-analysis. [18925401] Eur Radiol 19(3): 731-44 (2009)
2007 65	Case report: PET/CT, a cautionary tale. [17683560] BMC Cancer 7(-): 147 (2007)
2010 66	Positron emission tomography-computed tomography standardized uptake values in clinical practice and assessing response to therapy. [21147377] Semin Ultrasound CT MR 31(6): 496-505 (2010)

Downloaded from http://www.kidney.de - The Database of Free Medical Reviews - The Metatextbook of Medicine - Ossip Groth

All Medline data shown were primarily retrieved from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Fatal error: Uncaught Error: Call to undefined function mysql_connect() in C:\Inetpub\vhosts\kidney.de\httpdocs\bdom\Neoplasia (PET).php:92 Stack trace: #0 {main} thrown in C:\Inetpub\vhosts\kidney.de\httpdocs\bdom\Neoplasia (PET).php on line 92